DK3753929T3 - Dimere kontrastmidler - Google Patents

Dimere kontrastmidler Download PDF

Info

Publication number
DK3753929T3
DK3753929T3 DK20187182.9T DK20187182T DK3753929T3 DK 3753929 T3 DK3753929 T3 DK 3753929T3 DK 20187182 T DK20187182 T DK 20187182T DK 3753929 T3 DK3753929 T3 DK 3753929T3
Authority
DK
Denmark
Prior art keywords
contrast agents
dimer contrast
dimer
agents
contrast
Prior art date
Application number
DK20187182.9T
Other languages
English (en)
Inventor
Valeria Boi
Roberta Napolitano
Luciano Lattuada
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Application granted granted Critical
Publication of DK3753929T3 publication Critical patent/DK3753929T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • A61K49/122Macromolecular compounds dimers of complexes or complex-forming compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK20187182.9T 2015-12-10 2016-12-12 Dimere kontrastmidler DK3753929T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15199220 2015-12-10
EP16810346.3A EP3386954B1 (en) 2015-12-10 2016-12-12 Dimeric contrast agents

Publications (1)

Publication Number Publication Date
DK3753929T3 true DK3753929T3 (da) 2023-01-23

Family

ID=55027251

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16810346.3T DK3386954T3 (da) 2015-12-10 2016-12-12 Dimere kontrastmidler
DK20187182.9T DK3753929T3 (da) 2015-12-10 2016-12-12 Dimere kontrastmidler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16810346.3T DK3386954T3 (da) 2015-12-10 2016-12-12 Dimere kontrastmidler

Country Status (22)

Country Link
US (3) US10407412B2 (da)
EP (2) EP3753929B1 (da)
JP (1) JP6896733B2 (da)
KR (1) KR20180090823A (da)
CN (1) CN108368067B (da)
AU (1) AU2016368545C1 (da)
BR (1) BR112018010815B1 (da)
CA (1) CA3002897C (da)
DK (2) DK3386954T3 (da)
ES (2) ES2932302T3 (da)
FI (1) FI3753929T3 (da)
HR (2) HRP20221451T1 (da)
HU (2) HUE052680T2 (da)
IL (1) IL259836B (da)
LT (1) LT3386954T (da)
MX (1) MX2018007043A (da)
PL (2) PL3753929T3 (da)
PT (1) PT3386954T (da)
RU (1) RU2739834C2 (da)
SG (1) SG11201804412SA (da)
SI (2) SI3753929T1 (da)
WO (1) WO2017098044A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
HUE052680T2 (hu) * 2015-12-10 2021-05-28 Bracco Imaging Spa Dimer kontrasztanyagok
KR102464647B1 (ko) 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
CA3037803A1 (en) * 2016-12-12 2018-06-21 Bracco Imaging Spa Dimeric contrast agents
CA3120665A1 (en) 2018-11-23 2020-05-28 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
AU2020399182A1 (en) 2019-12-13 2022-06-09 Bracco Imaging Spa Manufacturing of protected DO3A
CA3185759A1 (en) 2020-07-27 2022-02-03 Andrea BARALE Manufacturing of dimeric contrast agents
JP2023551567A (ja) * 2020-12-04 2023-12-08 ブラッコ・イメージング・ソシエタ・ペル・アチオニ ガドテリドールの製造方法
AU2022317221A1 (en) 2021-07-27 2023-11-16 Bracco Imaging Spa Manufacturing of dimeric contrast agents
IL308882A (en) 2021-07-27 2024-01-01 Bracco Imaging Spa Process for the production of gadolinium complex solution
WO2023110863A1 (en) 2021-12-14 2023-06-22 Bracco Imaging Spa Process for manufacturing a mixture comprising a dimeric macrocycle intermediate of a gadolinium complex
WO2023110867A1 (en) 2021-12-14 2023-06-22 Bracco Imaging Spa Manufacturing of dimeric contrast agent
WO2024074648A1 (en) 2022-10-07 2024-04-11 Bracco Imaging Spa Precipitation and isolation of gadolinium complex

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
IT1292128B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
CA2309749A1 (en) * 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
DE19849465A1 (de) 1998-10-21 2000-04-27 Schering Ag Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
DE10117242C1 (de) * 2001-04-06 2002-05-16 Schering Ag Unsymmetrische dimere Metallkomplexe, Liganden für diese Metallkomplexe, Verfahren zu deren Herstellung, Arzneimittel bzw. Diagnosemittel, die die Metallkomplexe enthalten, insbesondere Kontrastmittel
US6852854B1 (en) * 2002-10-01 2005-02-08 Psiloquest Inc. Preformed carboxylated active ester for labeling biomolecules
US7208140B2 (en) 2003-02-19 2007-04-24 Schering Aktiengesellschaft Trimeric macrocyclic substituted benzene derivatives
WO2006002873A2 (en) * 2004-07-02 2006-01-12 Bracco Imaging Spa 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri )
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
RU2425831C2 (ru) * 2005-12-02 2011-08-10 Джи-И Хелткер АС Мультимерные контрастные агенты для магнитного резонанса
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
EP2457594A1 (en) * 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9315524B2 (en) 2012-05-07 2016-04-19 Kumar Ranjan Bhushan Magnetic resonance imaging agents for calcification
CN102727911B (zh) 2012-07-09 2013-07-24 中国科学院长春应用化学研究所 双氨基聚乙二醇修饰的顺磁性金属配合物磁共振成像造影剂
US9155804B2 (en) 2012-09-26 2015-10-13 General Electric Company Contrast enhancement agents and method of use thereof
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
HUE052680T2 (hu) * 2015-12-10 2021-05-28 Bracco Imaging Spa Dimer kontrasztanyagok

Also Published As

Publication number Publication date
BR112018010815B1 (pt) 2022-05-17
EP3386954B1 (en) 2020-12-02
PT3386954T (pt) 2021-01-07
RU2018123572A (ru) 2020-01-13
JP6896733B2 (ja) 2021-06-30
CA3002897A1 (en) 2017-06-15
NZ741900A (en) 2021-10-29
AU2016368545C1 (en) 2021-01-07
US10407412B2 (en) 2019-09-10
PL3386954T3 (pl) 2021-06-14
US20200331893A9 (en) 2020-10-22
EP3753929A1 (en) 2020-12-23
ES2932302T3 (es) 2023-01-17
US20190345142A1 (en) 2019-11-14
CN108368067B (zh) 2022-04-29
KR20180090823A (ko) 2018-08-13
HRP20210061T1 (hr) 2021-03-05
HRP20221451T1 (hr) 2023-02-17
DK3386954T3 (da) 2021-02-15
MX2018007043A (es) 2018-08-15
FI3753929T3 (fi) 2023-01-31
RU2018123572A3 (da) 2020-02-10
AU2016368545A1 (en) 2018-05-10
CN108368067A (zh) 2018-08-03
RU2739834C2 (ru) 2020-12-28
US11401262B2 (en) 2022-08-02
BR112018010815A2 (pt) 2018-11-27
US10882849B2 (en) 2021-01-05
CA3002897C (en) 2022-03-29
ES2843998T3 (es) 2021-07-21
HUE052680T2 (hu) 2021-05-28
SG11201804412SA (en) 2018-06-28
IL259836A (en) 2018-07-31
EP3386954A1 (en) 2018-10-17
US20180362511A1 (en) 2018-12-20
SI3386954T1 (sl) 2021-02-26
US20210024500A1 (en) 2021-01-28
AU2016368545B2 (en) 2020-09-03
WO2017098044A1 (en) 2017-06-15
PL3753929T3 (pl) 2023-03-13
HUE060536T2 (hu) 2023-03-28
IL259836B (en) 2021-07-29
JP2019501153A (ja) 2019-01-17
SI3753929T1 (sl) 2023-01-31
EP3753929B1 (en) 2022-10-26
LT3386954T (lt) 2021-04-12

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3753929T3 (da) Dimere kontrastmidler
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3331528T3 (da) Muskarinagonister
DK3360890T3 (da) Genterapi
DK3310450T3 (da) Olie-vand-separator
DK3331529T3 (da) Muskarinagonister
DK3270930T3 (da) Præeklampsi
DK3292136T3 (da) Penicillin-g-acylaser
DK3394281T3 (da) Gærcelle
DE112015006486A5 (de) Inkubationsrinne
DK3318308T3 (da) Badmintonketsjer
DK3274482T3 (da) Stenborsknop
DE112016005599A5 (de) Strahlungsgrill
DE112015005898A5 (de) Gurtschlossbringer
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
DE112016001124A5 (de) Spannschutz
FI11070U1 (fi) Kantojyrsin
DE102015000551A8 (de) Rotationszerstäuberturbine
DE102015226549B8 (de) Hybridheizmodul
ES1158483Y (es) Lucy-clip